ZVRA: McFarlane Neil F. sold $225K of stock
By AlphaYouPublished Form 4
McFarlane Neil F.
Reporting filer
McFarlane Neil F. reported selling 20,000 shares of Zevra Therapeutics, Inc. for about $225K ($11.25 a share on average). Form 4 filed Oct 13, 2026 lists 3 entries.
See the price move since this trade →
- Disclosed
- Oct 13, 2026
Reported details
3 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | McFarlane Neil F. | 2026-10-10 | M | Exercise or conversion | 50000 | Not stated (see footnotes) | 437,225 | 3 days | Filed terms
|
| Common Stock | McFarlane Neil F. | 2026-10-12 | S | Sale | 20000 | 11.2474 | 417,225 | 1 day | Filed terms
|
| Restricted Stock Unit (derivative) | McFarlane Neil F. | 2026-10-10 | M | Exercise or conversion | 50000 | 0 | 50,000 | 3 days | Filed terms
|
Common Stock
- Owner
- McFarlane Neil F.
- Date
- 2026-10-10
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 50000
- Price
- Not stated (see footnotes)
- Following holdings
- 437,225
- Reporting delay
- 3 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-10
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: 0
- transaction Shares: 50000
- id: F1
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 437225
- direct Or Indirect Ownership: D
Common Stock
- Owner
- McFarlane Neil F.
- Date
- 2026-10-12
- Code
- S
- Action
- Sale
- Quantity
- 20000
- Price
- 11.2474
- Following holdings
- 417,225
- Reporting delay
- 1 day
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-12
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: 0
- id: F2
- transaction Shares: 20000
- transaction Price Per Share: 11.2474
- id: F3
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 417225
- direct Or Indirect Ownership: D
Restricted Stock Unit (derivative)
- Owner
- McFarlane Neil F.
- Date
- 2026-10-10
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 50000
- Price
- 0
- Following holdings
- 50,000
- Reporting delay
- 3 days
- Filed terms and references
Filed terms
- security Title: Restricted Stock Unit
- conversion Or Exercise Price: 0
- id: F1
- transaction Date: 2026-10-10
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: 0
- transaction Shares: 50000
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: D
- id: F4
- id: F4
- underlying Security Title: Common Stock
- underlying Security Shares: 50000
- shares Owned Following Transaction: 50000
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- McFarlane Neil F.: President and CEO, Director.
- The filing reports a Rule 10b5-1 trading plan.
- F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F2: Adoption date of referenced 10b5-1(c) plan is: 03-25-2026
- F3: This transaction was executed in multiple trades at prices ranging from $11.07 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4: 25% of the RSUs vested and settled on each of October 10, 2024, October 10, 2025 and October 10, 2026. The remaining 25% of the shares will vest on 10/10/2027, provided that at the relevant vesting date the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.
Original sources
Prepared automatically from public filing data. Report a correction.